Dominari (DOMH) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Document Information Line Items
Entity Registrant Name	AIKIDO PHARMA INC.
Trading Symbol	AIKI
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		89,681,146
Amendment Flag	false
Entity Central Index Key	0000012239
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-05576
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	52-0849320
Entity Address, Address Line One	One Rockefeller Plaza
Entity Address, Address Line Two	11th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10020
City Area Code	703
Local Phone Number	992-9325
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 5,948	$ 2,715
Marketable securities	80,525	24,801
Prepaid expenses and other assets	644	215
Short-term investment	6,274
Deposits	4,420
Total current assets	97,811	27,731
Convertible note receivable	2,107
Investments	5,066	2,764
Total assets	104,984	30,495
Current liabilities
Accounts payable and accrued expenses	1,572	567
Accrued salaries and benefits	237	310
Total current liabilities	1,809	877
Total liabilities	1,809	877
Commitments and contingencies
Stockholders’ equity
Preferred stock, $.0001 par value, 50,000,000 Authorized
Common stock, $0.0001 par value, 100,000,000 shares authorized; 89,681,149 and 34,920,222 shares issued at September 30, 2021 and December 31, 2020, respectively; 89,681,146 and 34,920,219 shares outstanding at September 30, 2021 and December 31, 2020, respectively	9	3
Additional paid-in capital	265,394	186,482
Treasury stock, at cost, 3 shares at September 30, 2021 and December 31, 2020	(264)	(264)
Accumulated deficit	(161,964)	(156,603)
Total stockholders’ equity	103,175	29,618
Total liabilities and stockholders’ equity	104,984	30,495
Series D Preferred Stock
Stockholders’ equity
Preferred stock, $.0001 par value, 50,000,000 Authorized
Series D-1 Preferred Stock
Stockholders’ equity
Preferred stock, $.0001 par value, 50,000,000 Authorized

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	50,000,000	50,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	89,681,149	34,920,222
Common stock, shares outstanding	89,681,146	34,920,219
Series D Preferred Stock
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	4,725	4,725
Preferred stock, outstanding	4,725	4,725
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001
Series D-1 Preferred Stock
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	834	834
Preferred stock, outstanding	834	834
Liquidation preference (in Dollars per share)	$ 0.0001	$ 0.0001

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating costs and expenses
General and administrative	$ 1,676	$ 734	$ 5,231	$ 3,054
Research and development	100	191	497	951
Research and development - license acquired	3	41	1,128	1,154
Total operating expenses	1,779	966	6,856	5,159
Loss from operations	(1,779)	(966)	(6,856)	(5,159)
Other income (expenses)
Other income		4	135	19
Interest income	40		107
Loss on marketable securities	(3,033)	(433)	(2,574)	(171)
Change in fair value of investment	4,725	(622)	3,827	(7,352)
Total other income (expenses)	1,732	(1,051)	1,495	(7,504)
Net loss	$ (47)	$ (2,017)	$ (5,361)	$ (12,663)
Net loss per share, basic and diluted
Basic and Diluted (in Dollars per share)	$ 0	$ (0.06)	$ (0.07)	$ (0.49)
Weighted average number of shares outstanding, basic and diluted
Basic and Diluted (in Shares)	89,632,233	34,986,885	79,944,095	25,753,040

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Preferred Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2019			$ 155,062	$ (264)	$ (144,266)	$ 10,532
Balance (in Shares) at Dec. 31, 2019	4,825,549	5,559		3
Issuance of common stock and warrants (net of offering costs of $8,260)			6,559			6,559
Issuance of common stock and warrants (net of offering costs of $8,260) (in Shares)	3,245,745
Issuance of common stock, net of offering cost (net of offering costs of $1,905)	$ 2		17,843			17,845
Issuance of common stock, net of offering cost (net of offering costs of $1,905) (in Shares)	16,090,909
Common warrant and prefunded warrant exercise	$ 1		7,203			7,204
Common warrant and prefunded warrant exercise (in Shares)	10,758,016
Distribution of Hoth common stock			(269)			(269)
Net loss					(12,663)	(12,663)
Balance at Sep. 30, 2020	$ 3		186,398	$ (264)	(156,929)	29,208
Balance (in Shares) at Sep. 30, 2020	34,920,219	5,559		3
Balance at Jun. 30, 2020	$ 3		186,667	$ (264)	(154,912)	31,494
Balance (in Shares) at Jun. 30, 2020	34,920,219	5,559		3
Distribution of Hoth common stock			(269)			(269)
Distribution of Hoth common stock (in Shares)
Net loss					(2,017)	(2,017)
Balance at Sep. 30, 2020	$ 3		186,398	$ (264)	(156,929)	29,208
Balance (in Shares) at Sep. 30, 2020	34,920,219	5,559		3
Balance at Dec. 31, 2020	$ 3		186,482	$ (264)	(156,603)	29,618
Balance (in Shares) at Dec. 31, 2020	34,920,219	5,559		3
Issuance of common stock and warrants (net of offering costs of $8,260)	$ 6		77,983			77,989
Issuance of common stock and warrants (net of offering costs of $8,260) (in Shares)	53,905,927
Exercise of warrants			84			84
Exercise of warrants (in Shares)	80,000
Issuance of common stock for research and development license acquired			531			531
Issuance of common stock for research and development license acquired (in Shares)	625,000
Stock-based compensation			314			314
Stock-based compensation (in Shares)	150,000
Net loss					(5,361)	(5,361)
Balance at Sep. 30, 2021	$ 9		265,394	$ (264)	(161,964)	103,175
Balance (in Shares) at Sep. 30, 2021	89,681,146	5,559		3
Balance at Jun. 30, 2021	$ 9		265,255	$ (264)	(161,917)	103,083
Balance (in Shares) at Jun. 30, 2021	89,531,146	5,559		3
Stock-based compensation			139			139
Stock-based compensation (in Shares)	150,000
Net loss					(47)	(47)
Balance at Sep. 30, 2021	$ 9		$ 265,394	$ (264)	$ (161,964)	$ 103,175
Balance (in Shares) at Sep. 30, 2021	89,681,146	5,559		3

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Statement of Stockholders' Equity [Abstract]
Warrant net offering costs	$ 8,260	$ 941
Net of offering costs		$ 1,905

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (5,361)	$ (12,663)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of investment	(3,827)	7,352
Research and development-acquired license, expensed	1,128	1,154
Stock-based compensation	314
Realized gain on marketable securities	(501)	(97)
Unrealized loss on marketable securities	4,296	781
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(429)	135
Accounts payable and accrued expenses	5	30
Accrued salaries and benefits	(73)	(321)
Interest receivable on convertible note	(107)
Payable to DatChat		50
Net cash used in operating activities	(4,555)	(3,579)
Cash flows from investing activities
Purchase of marketable securities	(90,541)	(98,524)
Sale of marketable securities	30,439	72,008
Proceeds from sale of Hoth common shares		460
Proceeds from sale of DatChat common shares	900
Funds to deposit accounts, net	(4,420)
Purchase of investments	(4,066)
Purchase of research and development licenses	(597)	(1,154)
Purchase of convertible note	(2,000)
Net cash used in investing activities	(70,285)	(27,210)
Cash flows from financing activities
Proceeds from issuance of common stock and warrants, net of offering cost	77,989	6,559
Proceeds from issuance of common stock, net of offering cost		17,845
Proceeds from exercise of warrants	84	7,204
Net cash provided by financing activities	78,073	31,608
Net increase in cash and cash equivalents	3,233	819
Cash and cash equivalents, beginning of period	2,715	91
Cash and cash equivalents, end of period	5,948	910
Non-cash investing and financing activities
Distribution of Hoth common stock		$ 269
Unpaid investment	$ 1,000

Organization and Description of

Organization and Description of Business and Recent Developments	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Organization and Description of Business and Recent Developments	Note 1. Organization and Description of Business and Recent Developments Organization and Description of Business AIkido Pharma Inc. (the “Company” and “We”), formerly known as Spherix Incorporated, was initially formed in 1967. Since 2017, the Company has operated as a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The Company’s pipeline consists of patented technology from leading universities and researchers. The Company is currently in the process of developing its innovative therapeutic drug pipeline through strong partnerships with world renowned educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. The Company’s oncology therapeutics include prospective treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The Company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. As a result of the Company’s biotechnology research and development and associated investments and acquisitions, its business portfolio now focuses on the treatment of three different cancers and multiple types of viral infections. The Company’s pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a new compound that it hopes will become the next generation of chemotherapy treatment for advanced pancreatic cancer. DHA-dFdC overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated in preclinical toxicity tests. Preclinical studies have also indicated that DHA-dFdC inhibits pancreatic cancer cell growth (up to 100,000-fold more potent that gemcitabine, a current standard therapy), targets pancreatic tumors and has demonstrated activities against other cancers. The Company has also executed a Sponsored Research Agreement with UMB to support the development of the technology under the direction of these inventors at UMB.

Liquidity and Capital Resources

Liquidity and Capital Resources	9 Months Ended
	Sep. 30, 2021
Going Concern And Financial Condition [Abstract]
Liquidity and Capital Resources	Note 2. Liquidity and Capital Resources The Company continues to incur ongoing administrative and other expenses, including public company expenses, in excess of corresponding (non-financing related) revenue. While the Company continues to implement its business strategy, it intends to finance its activities through managing current cash on hand from the Company’s past debt and equity offerings. During the first quarter of 2021, the Company consummated a public offering of 53,905,927 shares of common stock (including the underwriter overallotment). The Company received net proceeds of approximately $78.0 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Based upon projected cash flow requirements, the Company has adequate cash to fund its operations for at least the next twelve months from the date of the issuance of these consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Nuta Technology Corp. (“Nuta”), Spherix Portfolio Acquisition II, Inc. (“SPAII”), Guidance IP, LLC (“Guidance”), Directional IP, LLC (“Directional”), Spherix Management Services, LLC (“SMS”), Spherix Delaware Merger Sub Inc. (“Merger Sub”), Spherix Merger Subsidiary, Inc (“SMSI”) and NNPT, LLC (“NNPT”). All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of September 30, 2021, condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020, condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or for any future interim period. The condensed consolidated balance sheet at December 31, 2020 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2020 and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on March 25, 2021. Use of Estimates The accompanying condensed consolidated financial statements have been prepared in conformity with US GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of convertible note and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions. Significant Accounting Policies Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on March 25, 2021. Fair Value Option - Convertible Note The guidance in ASC 825, Financial Instruments Deposits In April 2021, the Company deposited $5 million with a fund to identify opportunities to expand the Company’s core business strategies in Asia. The cash are held in bank accounts on behalf of the Company until the fund manager identifies investments. During the nine and three months ended September 30, 2021, the Company incurred advisory fees of approximately $0.6 million and $56,000, respectively, and the balance held in cash in this fund was $4.4 million as of September 30, 2021. Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

License agreement with Silo Pha

License agreement with Silo Pharma Inc.	9 Months Ended
	Sep. 30, 2021
License Agreement With Other Companies [Abstract]
License agreement with Silo Pharma Inc.	Note 4. License agreement with Silo Pharma Inc. Effective January 5, 2021, the Company entered into an exclusive patent license agreement (the “License Agreement”) with Silo Pharma Inc., a Delaware corporation and Silo Pharma Inc., a Florida corporation, and their affiliates/subsidiaries (collectively, “Silo Pharma”). On April 12, 2021, the Company entered into an amendment to the License Agreement (“Amendment”). The Amendment amended a portion of the license fees included in the original License Agreement and exchange 500 shares of the Company’s Series M Convertible Preferred Stock to an aggregate of 625,000 restricted shares of the Company’s common stock, par value $0.001 per share, effective as of January 5, 2021. The Company paid a one-time nonrefundable cash payment of $0.5 million to Silo Pharma. The Company shall also pay Silo Pharma a running royalty equal to 2% of “net sales” (as such term is defined in the License Agreement). Running royalties are amounts paid to the licensor over time based on the revenue earned by the licensee from sales of products that embody the licensed IP, if any.

Investments in Marketable Secur

Investments in Marketable Securities	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Investments in Marketable Securities	Note 5. Investments in Marketable Securities The realized gain or loss, unrealized gain or loss, and dividend income related to marketable securities for the three and nine months ended September 30, 2021 and 2020, which are recorded as a component of gains and (losses) on marketable securities on the consolidated statements of operations (excluding a $70,000 distribution to CBM shareholders during the nine months ended September 30, 2020), are as follows ($ in thousands): For the Three Months Ended For the Nine Months Ended 2021 2020 2021 2020 Realized gain (loss) $ (583 ) $ (447 ) $ 501 $ 97 Unrealized loss (2,901 ) (166 ) (4,296 ) (781 ) Dividend income 451 180 1,221 439 Interest income - - - 4 $ (3,033 ) $ (433 ) $ (2,574 ) $ (241 )

Short-term investment - investm

Short-term investment - investment in Hoth Therapeutics, Inc.	9 Months Ended
	Sep. 30, 2021
Investment In Hoth Therapeutics Inc Abstract [Abstract]
Short-term investment - investment in Hoth Therapeutics, Inc.	Note 6. Short-term investment - investment in Hoth Therapeutics, Inc. The following summarizes the Company investment in Hoth as of September 30, 2021: Security Name Shares Fair value Fair value HOTH 1,166,415 $ 1.19 $ 1,388

Short-term investment - inves_2

Short-term investment - investment in DatChat, Inc.	9 Months Ended
	Sep. 30, 2021
Shortterm Investment Investment In Dat Chat Inc [Abstract]
Short-term investment - investment in DatChat, Inc.	Note 7. Short-term investment - investment in DatChat, Inc. DatChat, Inc. (“DatChat”) is a communications software company that gives users the ability to communicate with privacy and protection. On August 17, 2021, DatChat closed its initial public offering (the “IPO”) at an initial offering price to the public of $4.15 per share under the ticker DATS. The Company records this investment at fair value and records any change in fair value in the statements of operations (see Note 9). On September 22, 2021, the Company entered into a certain Stock Transfer Agreement, by and between the Company and a purchaser, and sold 167,084 shares of DatChat common stock for net proceeds of approximately $0.9 million. The following summarizes the Company investment in DatChat as of September 30, 2021: Security Name Shares Fair value Fair value DATS 357,916 $ 13.65 $ 4,886

Other Investments

Other Investments	9 Months Ended
	Sep. 30, 2021
Other Investments [Abstract]
Other Investments	Note 8. Other Investments The Company has made an accounting policy election to adopt an adjusted cost method measurement alternative for the below investments pursuant to ASU 2016-01. Investment in Kerna Health Inc On September 15, 2021, the Company entered into a securities purchase agreement (the “Kerna Securities Purchase Agreement”) with Kerna Health Inc., (“Kerna”). Under the Kerna Securities Purchase Agreement, the Company agreed to purchase 1,333,334 shares of common stock of Kerna for $1.0 million. Investment in Kaya Holding Corp On September 29, 2021, the Company entered into a securities purchase agreement (the “Kaya Securities Purchase Agreement”) with Kaya Holding Corp., (“Kaya”). Under the Kaya Securities Purchase Agreement, the Company agreed to purchase 8,325,000 shares of common stock of Kaya for approximately $0.7 million. Investment in Tevva Motors On September 22, 2021, the Company entered into a securities purchase agreement (the “Tevva Motors Subscription Agreement”) with Big Sky Opportunities Fund, LLC, who handled the offering for Tevva Motors. Under the Tevva Motors Subscription Agreement, the Company agreed to purchase 29,004 Interests of Tevva Motors for approximately $1.0 million. Subsequently, on September 30, 2021, the Company entered into a second securities purchase agreement with Big Sky Opportunities Fund, LLC to purchase an additional 29,004 Interests of Tevva Motors for approximately $1.0 million. Investment in Slinger Bag Inc On August 6, 2021, the Company entered into a securities purchase agreement (the “Slinger Bag Securities Purchase Agreement”) with Slinger Bag Inc., (“Slinger Bag”). Under the Slinger Bag Securities Purchase Agreement, the Company agreed to pay $1.4 million to Slinger Bag for the issuance of a convertible promissory note in the principal amount of $1.4 million and a common stock purchase warrant.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities	Note 9. Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example, cash flow modeling inputs based on assumptions) Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company's market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. The following table presents the Company’s assets and liabilities that are measured at fair value at September 30, 2021 and December 31, 2020 ($ in thousands): Fair value measured at September 30, 2021 Total at Quoted Significant Significant 2021 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 60,589 $ 60,589 $ - $ - Mutual fund securities $ 16,896 $ 16,896 $ - $ - Unit Investments Trust $ 481 $ 481 $ - $ - Special purpose acquisition corps $ 2,559 $ 2,559 Total marketable securities $ 80,525 $ 80,525 $ - $ - Short-term investment $ 6,274 $ 6,274 $ - $ - Convertible note receivable $ 2,107 $ - $ - $ 2,107 Fair value measured at December 31, 2020 Total at Quoted Significant Significant 2020 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 24,274 $ 24,274 $ - $ - Mutual fund securities $ 527 $ 527 $ - $ - Total marketable securities $ 24,801 $ 24,801 $ - $ - Investments $ 2,764 $ 2,764 $ - $ - Level 3 Valuation Techniques The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis ($ in thousands): Fair Value of Level 3 September 30, December 31, Beginning balance $ - $ - Purchase of convertible note 2,000 - Accrued interest receivable 107 - Ending balance $ 2,107 $ - Convergent Investment On January 29, 2021, the Company purchased an 8% convertible promissory note (“Convertible Note”) issued by Convergent Therapeutics, Inc. (“Convergent”) in the principal amount of $2 million pursuant to a Note Purchase Agreement with Convergent. The Company paid a purchase price for the Convertible Note of $2 million. The Company will receive interest on the Convertible Note at the rate of 8% per annum payable upon conversion or maturity of the Convertible Note. The Convertible Note shall mature on January 29, 2023. The Company has elected to measure the purchase of the Convertible Note from Convergent using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in interest income and other, net in the condensed consolidated statements of operations. The Convertible Note is disclosed as a noncurrent Convertible Note investment in the condensed consolidated balance sheets. As of September 30, 2021, the fair value of the Convertible Note was measured at $2.0 million, taking into consideration cost of the investment, market participant inputs, market conditions, liquidity, operating results and other qualitative and quantitative factors. The value at which the Company’s Convertible Note is carried on its books is adjusted to estimated fair value at the end of each quarter, taking into account general economic and stock market conditions and those characteristics specific to the underlying investments. No change in fair value was recorded during the nine months ended September 30, 2021. Interest accrues on the unpaid principal balance on a quarterly basis and is recognized in interest income in the condensed consolidated statements of operations. The Company recorded an interest income receivable of approximately $107,000 on the Convertible Note as of September 30, 2021.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	Note 10. Net Loss per Share Basic loss per common share is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at September 30, 2021 and 2020 are as follows: As of As of September 30, 2021 2020 Convertible preferred stock 688 688 Warrants to purchase common stock 5,801,701 734,501 Options to purchase common stock 479,654 84,304 Total 6,282,043 819,493

Stockholders' Equity and Conver

Stockholders' Equity and Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity and Convertible Preferred Stock	Note 11. Stockholders’ Equity and Convertible Preferred Stock Public Offering On February 19, 2021, the Company consummated the public offering pursuant to an amended and restated underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative to the underwriters named therein (the “Underwriter”), pursuant to which the Company agreed to issue and sell to the Underwriter in an underwritten public offering (the “Offering”) an aggregate of 46,875,000 shares (the “Shares”) of common stock, $0.0001 par value per share, of the Company (the “Common Stock”). The Company received gross proceeds of approximately $75 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. On February 23, 2021, the Underwriter partially exercised its over-allotment option and purchased an additional 7,030,927 Shares, resulting in aggregate proceeds of approximately $86.2 million, before deducting underwriting discounts and commissions and other expenses. The total net proceeds received from these two offerings were approximately $78.0 million. In connection with the Offering, the Company issued the Underwriter warrants (the “Underwriter’s Warrants”) to purchase up to 4,312,473 shares of Common Stock, or 8% of the Shares sold in the Offering. The Underwriter’s Warrants will be exercisable for a period of five years from February 19, 2021 at an exercise price of $2.00 per share, subject to adjustment. Warrants A summary of warrant activity for the nine months ended September 30, 2021 is presented below: Warrants Weighted Total Weighted Outstanding as of December 31, 2020 1,723,020 $ 3.07 57,333 1.11 Issued 4,312,473 2.00 - 4.39 Exercised (80,000 ) 1.05 - - Expired (153,789 ) 19.67 - - Forfeited (3 ) 16.15 - - Outstanding as of September 30, 2021 5,801,701 $ 1.86 53,999 4.12 Stock Options A summary of stock option activity for the nine months ended September 30, 2021 is presented below: Number of Weighted Total Weighted Outstanding as of December 31, 2020 384,304 $ 40.15 $ 69,000 8.9 Employee options granted 100,000 1.24 - 9.3 Employee options expired (4,650 ) - - - Outstanding as of September 30, 2021 479,654 $ 32.35 $ 54,000 8.5 Options vested and exercisable 479,654 $ 32.35 $ 54,000 8.5 Stock-based compensation associated with the amortization of stock option expense was approximately $6,000 and $0 for the three months ended September 30, 2021 and 2020, respectively. Stock-based compensation associated with the amortization of stock option expense was approximately $0.2 million and $0 for the nine months ended September 30, 2021 and 2020, respectively. All stock compensation was recorded as a component of general and administrative expenses. Estimated future stock-based compensation expense relating to unvested stock options is approximately $0. Restricted Stock Awards Pursuant to the patent license agreement effective January 5, 2021 with Silo Parma Inc., the Company issued and delivered to Silo Pharma 625,000 shares of the Company’s restricted stock as consideration for the license of the licensed patents. This restricted stock award vested immediately. The Company recorded approximately $0.5 million in research and development expense related with license acquired during the nine months ended September 30, 2021 related to this arrangement. On July 31, 2021, the Company issued each of six directors 25,000 shares of the Company’s common stock pursuant to the Company’s 2020 Equity Incentive Plan. These shares have a total fair value of approximately $0.1 million. These restricted stock awards vested immediately.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies Legal Proceedings In the past, in the ordinary course of business, the Company actively pursued legal remedies to enforce its intellectual property rights and to stop unauthorized use of our technology. Other than ordinary routine litigation incidental to the business, we know of no material, active or pending legal proceedings against us. Risks and Uncertainties – COVID-19 Management continues to valuate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for drug candidates, the specific impact is not readily determinable as of the date of these consolidated financial statements. The COVID-19 pandemic has slowed down some drug development efforts and has slowed the acquisition of new drugs. However, the impact of the pandemic and ensuing lockdowns are easing. The process of drug development and further acquisitions is now continuing. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events The Company evaluated events that have occurred after the balance sheet date through the date the condensed consolidated financial statements were issued. Based upon the evaluation and transactions, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Nuta Technology Corp. (“Nuta”), Spherix Portfolio Acquisition II, Inc. (“SPAII”), Guidance IP, LLC (“Guidance”), Directional IP, LLC (“Directional”), Spherix Management Services, LLC (“SMS”), Spherix Delaware Merger Sub Inc. (“Merger Sub”), Spherix Merger Subsidiary, Inc (“SMSI”) and NNPT, LLC (“NNPT”). All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of September 30, 2021, condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020, condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021 or for any future interim period. The condensed consolidated balance sheet at December 31, 2020 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2020 and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on March 25, 2021.
Use of Estimates	Use of Estimates The accompanying condensed consolidated financial statements have been prepared in conformity with US GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include stock-based compensation, the valuation of investments, the valuation of convertible note and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.
Significant Accounting Policies	Significant Accounting Policies Other than as described below, there have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on March 25, 2021.
Fair Value Option - Convertible Note	Fair Value Option - Convertible Note The guidance in ASC 825, Financial Instruments
Deposits	Deposits In April 2021, the Company deposited $5 million with a fund to identify opportunities to expand the Company’s core business strategies in Asia. The cash are held in bank accounts on behalf of the Company until the fund manager identifies investments. During the nine and three months ended September 30, 2021, the Company incurred advisory fees of approximately $0.6 million and $56,000, respectively, and the balance held in cash in this fund was $4.4 million as of September 30, 2021.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2019-12, “ Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

Investments in Marketable Sec_2

Investments in Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of marketable securities	For the Three Months Ended For the Nine Months Ended 2021 2020 2021 2020 Realized gain (loss) $ (583 ) $ (447 ) $ 501 $ 97 Unrealized loss (2,901 ) (166 ) (4,296 ) (781 ) Dividend income 451 180 1,221 439 Interest income - - - 4 $ (3,033 ) $ (433 ) $ (2,574 ) $ (241 )

Short-term investment - inves_3

Short-term investment - investment in Hoth Therapeutics, Inc. (Tables)	9 Months Ended
	Sep. 30, 2021
Investment In Hoth Therapeutics Inc Abstract [Abstract]
Schedule of investment in Hoth	Security Name Shares Fair value Fair value HOTH 1,166,415 $ 1.19 $ 1,388

Short-term investment - inves_4

Short-term investment - investment in DatChat, Inc. (Tables)	9 Months Ended
	Sep. 30, 2021
Shortterm Investment Investment In Dat Chat Inc [Abstract]
Schedule of investment in DatChat	Security Name Shares Fair value Fair value DATS 357,916 $ 13.65 $ 4,886

Fair Value of Financial Asset_2

Fair Value of Financial Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of fair value assets and liabilities	Fair value measured at September 30, 2021 Total at Quoted Significant Significant 2021 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 60,589 $ 60,589 $ - $ - Mutual fund securities $ 16,896 $ 16,896 $ - $ - Unit Investments Trust $ 481 $ 481 $ - $ - Special purpose acquisition corps $ 2,559 $ 2,559 Total marketable securities $ 80,525 $ 80,525 $ - $ - Short-term investment $ 6,274 $ 6,274 $ - $ - Convertible note receivable $ 2,107 $ - $ - $ 2,107 Fair value measured at December 31, 2020 Total at Quoted Significant Significant 2020 (Level 1) (Level 2) (Level 3) Assets Marketable securities: Equities $ 24,274 $ 24,274 $ - $ - Mutual fund securities $ 527 $ 527 $ - $ - Total marketable securities $ 24,801 $ 24,801 $ - $ - Investments $ 2,764 $ 2,764 $ - $ -
Schedule of financial assets measured at fair value on a recurring basis	Fair Value of Level 3 September 30, December 31, Beginning balance $ - $ - Purchase of convertible note 2,000 - Accrued interest receivable 107 - Ending balance $ 2,107 $ -

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of potentially diluted loss per share	As of As of September 30, 2021 2020 Convertible preferred stock 688 688 Warrants to purchase common stock 5,801,701 734,501 Options to purchase common stock 479,654 84,304 Total 6,282,043 819,493

Stockholders' Equity and Conv_2

Stockholders' Equity and Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of warrant activity	Warrants Weighted Total Weighted Outstanding as of December 31, 2020 1,723,020 $ 3.07 57,333 1.11 Issued 4,312,473 2.00 - 4.39 Exercised (80,000 ) 1.05 - - Expired (153,789 ) 19.67 - - Forfeited (3 ) 16.15 - - Outstanding as of September 30, 2021 5,801,701 $ 1.86 53,999 4.12
Schedule of option activity	Number of Weighted Total Weighted Outstanding as of December 31, 2020 384,304 $ 40.15 $ 69,000 8.9 Employee options granted 100,000 1.24 - 9.3 Employee options expired (4,650 ) - - - Outstanding as of September 30, 2021 479,654 $ 32.35 $ 54,000 8.5 Options vested and exercisable 479,654 $ 32.35 $ 54,000 8.5

Liquidity and Capital Resourc_2

Liquidity and Capital Resources (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)shares
Liquidity and Capital Resources (Details) [Line Items]
Gross proceeds | $	$ 78
Underwriter Overallotment [Member]
Liquidity and Capital Resources (Details) [Line Items]
Shares of common stock | shares	53,905,927

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Apr. 30, 2021
Accounting Policies [Abstract]
Deposits			$ 5,000
Balance held in cash	$ 600	$ 600
Advisory fees	$ 56,000
Cash		$ 4,400

License agreement with Silo P_2

License agreement with Silo Pharma Inc. (Details) $ / shares in Units, $ in Millions	Apr. 12, 2021USD ($)$ / sharesshares
License agreement with Silo Pharma Inc. (Details) [Line Items]
Exchange shares	500
Nonrefundable cash payment (in Dollars) | $	$ 0.5
Net sales percentage	2.00%
Series M Convertible Preferred Stock [Member]
License agreement with Silo Pharma Inc. (Details) [Line Items]
Aggregate of restricted shares	625,000
Par value per shares (in Dollars per share) | $ / shares	$ 0.001

Investments in Marketable Sec_3

Investments in Marketable Securities (Details)	9 Months Ended
	Sep. 30, 2021USD ($)
Investments, Debt and Equity Securities [Abstract]
Investments in marketable securities	$ 70,000

Investments in Marketable Sec_4

Investments in Marketable Securities (Details) - Schedule of marketable securities - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Schedule of marketable securities [Abstract]
Realized gain (loss)	$ (583)	$ (447)	$ 501	$ 97
Unrealized gain (loss)	(2,901)	(166)	(4,296)	(781)
Dividend income	451	180	1,221	439
Interest income				4
Total	$ (3,033)	$ (433)	$ (2,574)	$ (241)

Short-term investment - inves_5

Short-term investment - investment in Hoth Therapeutics, Inc. (Details) - Schedule of investment in Hoth - HOTH [Member] $ / shares in Units, $ in Thousands	Sep. 30, 2021USD ($)$ / sharesshares
Short-term investment - investment in Hoth Therapeutics, Inc. (Details) - Schedule of investment in Hoth [Line Items]
Shares Owned | shares	1,166,415
Fair value per Share | $ / shares	$ 1.19
Fair value | $	$ 1,388

Short-term investment - inves_6

Short-term investment - investment in DatChat, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Sep. 22, 2021	Aug. 17, 2021
IPO [Member]
Short-term investment - investment in DatChat, Inc. (Details) [Line Items]
Price per share		$ 4.15
DatChat [Member]
Short-term investment - investment in DatChat, Inc. (Details) [Line Items]
Shares issued	167,084
Net proceeds	$ 0.9

Short-term investment - inves_7

Short-term investment - investment in DatChat, Inc. (Details) - Schedule of investment in DatChat - DATS [Member] $ / shares in Units, $ in Thousands	Sep. 30, 2021USD ($)$ / sharesshares
Short-term investment - investment in DatChat, Inc. (Details) - Schedule of investment in DatChat [Line Items]
Shares Owned | shares	357,916
Fair value per Share | $ / shares	$ 13.65
Fair value | $	$ 4,886

Other Investments (Details)

Other Investments (Details) - USD ($) $ in Millions	Oct. 06, 2021	Sep. 30, 2021	Sep. 29, 2021	Sep. 22, 2021	Sep. 15, 2021
Kerna Health Inc [Member]
Other Investments (Details) [Line Items]
Purchase shares					1,333,334
Other investment					$ 1
Kaya Holding Corp [Member]
Other Investments (Details) [Line Items]
Purchase shares			8,325,000
Other investment			$ 0.7
Tevva Motors [Member]
Other Investments (Details) [Line Items]
Purchase shares		29,004		29,004
Other investment		$ 1		$ 1
Slinger Bag Inc [Member] | Subsequent Event [Member]
Other Investments (Details) [Line Items]
Purchase shares	1,400,000
Other investment	$ 1.4

Fair Value of Financial Asset_3

Fair Value of Financial Assets and Liabilities (Details) - USD ($)	1 Months Ended	9 Months Ended
	Jan. 29, 2021	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Purchase of percentage	8.00%
Principal amount	$ 2,000,000
Purchase price of convertible note	$ 2,000,000
Fair value measurement of maturity rate	8.00%
Fair value amount		$ 2,000,000
Interest income receivable		$ 107,000

Fair Value of Financial Asset_4

Fair Value of Financial Assets and Liabilities (Details) - Schedule of fair value assets and liabilities - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Equities	$ 60,589	$ 24,274
Mutual fund securities	16,896	527
Unit Investments Trust	481
Special purpose acquisition corps	2,559
Total marketable securities	80,525	24,801
Short-term investment	6,274
Convertible note receivable	2,107
Marketable securities:
Investments		2,764
Quoted prices in active markets (Level 1) [Member]
Assets
Equities	60,589	24,274
Mutual fund securities	16,896	527
Unit Investments Trust	481
Special purpose acquisition corps	2,559
Total marketable securities	80,525	24,801
Short-term investment	6,274
Convertible note receivable
Marketable securities:
Investments		2,764
Significant other observable inputs (Level 2) [Member]
Assets
Equities
Mutual fund securities
Unit Investments Trust
Total marketable securities
Short-term investment
Convertible note receivable
Marketable securities:
Investments
Significant unobservable inputs (Level 3) [Member]
Assets
Equities
Mutual fund securities
Unit Investments Trust
Total marketable securities
Short-term investment
Convertible note receivable	$ 2,107
Marketable securities:
Investments

Fair Value of Financial Asset_5

Fair Value of Financial Assets and Liabilities (Details) - Schedule of financial assets measured at fair value on a recurring basis - Fair Value of Level 3 investment [Member] - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Fair Value of Financial Assets and Liabilities (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Beginning balance
Purchase of convertible note	2,000
Accrued interest receivable	107
Ending balance	$ 2,107

Net Loss per Share (Details) -

Net Loss per Share (Details) - Schedule of potentially diluted loss per share - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,282,043	819,493
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	688	688
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,801,701	734,501
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	479,654	84,304

Stockholders' Equity and Conv_3

Stockholders' Equity and Convertible Preferred Stock (Details) - USD ($)	Feb. 19, 2021	Jan. 05, 2021	Jul. 31, 2021	Feb. 23, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Stockholders' Equity and Convertible Preferred Stock (Details) [Line Items]
Common stock, par value (in Dollars per share)					$ 0.0001		$ 0.0001		$ 0.0001
Received gross proceeds	$ 75,000,000
Net proceeds received				$ 78,000,000
Amortization of stock option expense					$ 6,000	$ 0	$ 200,000	$ 0
Stock-based compensation expense							0
Research and development expense							$ 500,000
Common stock share issued (in Shares)			25,000
Restricted stock			$ 100,000
Public Offering [Member]
Stockholders' Equity and Convertible Preferred Stock (Details) [Line Items]
Aggregate shares of common stock (in Shares)	46,875,000
Common stock, par value (in Dollars per share)	$ 0.0001
Over-Allotment Option [Member]
Stockholders' Equity and Convertible Preferred Stock (Details) [Line Items]
Aggregate shares of common stock (in Shares)				7,030,927
Received gross proceeds				$ 86,200,000
Underwriter’s Warrants [Member]
Stockholders' Equity and Convertible Preferred Stock (Details) [Line Items]
Aggregate shares of common stock (in Shares)							4,312,473
Percentage of stock sold							8.00%
Exercise price per share (in Dollars per share)	$ 2
Silo Parma Inc [Member]
Stockholders' Equity and Convertible Preferred Stock (Details) [Line Items]
Shares of restricted shares (in Shares)		625,000

Stockholders' Equity and Conv_4

Stockholders' Equity and Convertible Preferred Stock (Details) - Schedule of warrant activity - Warrant [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Class of Warrant or Right [Line Items]
Outstanding beginning balance, Warrants | shares	1,723,020
Outstanding beginning balance, Weighted Average Exercise Price | $ / shares	$ 3.07
Outstanding beginning balance, Intrinsic Value | $	$ 57,333
Outstanding beginning balance, Weighted Average Remaining Contractual Life	1 year 1 month 9 days
Outstanding ending balance, Warrants | shares	5,801,701
Outstanding ending balance, Weighted Average Exercise Price | $ / shares	$ 1.86
Outstanding ending balance, Intrinsic Value | $	$ 53,999
Outstanding ending balance, Weighted Average Remaining Contractual Life	4 years 1 month 13 days
Issued, Warrants | shares	4,312,473
Issued, Weighted Average Exercise Price | $ / shares	$ 2
Issued, Intrinsic Value | $
Issued, Weighted Average Remaining Contractual Life	4 years 4 months 20 days
Exercised, Warrants | shares	(80,000)
Exercised, Weighted Average Exercise Price | $ / shares	$ 1.05
Exercised, Intrinsic Value | $
Expired, Warrants | shares	(153,789)
Expired, Weighted Average Exercise Price | $ / shares	$ 19.67
Expired, Intrinsic Value | $
Forfeited, Warrants | shares	(3)
Forfeited, Weighted Average Exercise Price | $ / shares	$ 16.15
Forfeited, Intrinsic Value | $

Stockholders' Equity and Conv_5

Stockholders' Equity and Convertible Preferred Stock (Details) - Schedule of option activity $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Schedule of option activity [Abstract]
Outstanding beginning balance, Number of Shares | shares	384,304
Outstanding beginning balance, Weighted Average Exercise Price | $ / shares	$ 40.15
Outstanding beginning balance, Intrinsic Value | $	$ 69,000
Outstanding beginning balance, Weighted Average Remaining Contractual Life	8 years 10 months 24 days
Outstanding ending balance, Number of Shares | shares	479,654
Outstanding ending balance, Weighted Average Exercise Price | $ / shares	$ 32.35
Outstanding ending balance, Intrinsic Value | $	$ 54,000
Outstanding ending balance, Weighted Average Remaining Contractual Life	8 years 6 months
Options vested and exercisable, Number of Shares | shares	479,654
Options vested and exercisable, Weighted Average Exercise Price | $ / shares	$ 32.35
Options vested and exercisable, Intrinsic Value | $	$ 54,000
Options vested and exercisable, Weighted Average Remaining Contractual Life	8 years 6 months
Employee options granted, Number of Shares | shares	100,000
Employee options granted, Weighted Average Exercise Price | $ / shares	$ 1.24
Employee options granted, Intrinsic Value | $
Employee options granted, Weighted Average Remaining Contractual Life (in years)	9 years 3 months 18 days
Employee options expired, Number of Shares | shares	(4,650)
Employee options expired, Weighted Average Exercise Price | $ / shares
Employee options expired, Intrinsic Value | $